Semaglutide and pregnancy.

Advanced Search

Kenneth Skov, Ida Nikoline Mandic, Kathinka Marie Nyborg

Author Information

Kenneth Skov: Clinical Pharmacology Unit, Zealand University Hospital Roskilde, Roskilde, Denmark. ORCID
Ida Nikoline Mandic: Pediatric Unit, Slagelse Hospital, Slagelse, Denmark.
Kathinka Marie Nyborg: Department of Obstetrics and Gynecology, Fetal Medicine Unit, Slagelse Hospital, Slagelse, Denmark.

PMID: 37688299 DOI: 10.1002/ijgo.15092

No abstract text available.

PCOS case report malformations overweight pregnancy risk pregnancy semaglutide untoward fetal outcome

Zhao X, Wang M, Wen Z, et al. GLP-1 receptor agonists: beyond their pancreatic effects. Front Endocrinol. 2021;12:721135. doi:10.3389/fendo.2021.721135

Jensterle M, Janez A, Fliers E, DeVries JH, Vrtacnik-Bokal E, Siegelaar SE. The role of glucagon-like peptide-1 in reproduction: from physiology to therapeutic perspective. Hum Reprod Update. 2019;25:504-517. doi:10.1093/humupd/dmz019

31/03/2023 Ozempic - EMEA/H/C/004174 - PSUSA/00010671/202205. https://www.ema.europa.eu/documents/product-information/ozempic-epar-productinformation_en.pdf (Accessed September 1, 2023)

Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24:1553-1564. doi:10.1111/dom.14725

Female

Humans

Pregnancy

Diabetes Mellitus, Type 2

Glucagon-Like Peptides

Hypoglycemic Agents

Overweight

Pregnancy Outcome

Glucagon-Like Peptides

Hypoglycemic Agents

semaglutide

Journal Article

OpenLB
Open Library of Bioscience